T1	Participants 22 100	f macrovascular events in patients with type 2 diabetes in the PROactive Study
T2	Participants 230 313	2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke
T3	Participants 487 609	to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes
T4	Participants 672 748	5238 patients with type 2 diabetes who had evidence of macrovascular disease
T5	Participants 871 885	15 mg to 45 mg
T6	Participants 896 1002	r matching placebo (n=2633), to be taken in addition to their glucose-lowering drugs and other medications
T7	Participants 1293 1311	intention to treat
T8	Participants 1396 1422	number ISRCTN NCT00174993.
T9	Participants 1344 1395	International Standard Randomised Controlled Trial,
T10	Participants 1536 1547	34.5 months
T11	Participants 1549 1620	514 of 2605 patients in the pioglitazone group and 572 of 2633 patients
T12	Participants 1852 1864	301 patients
T13	Participants 1895 1941	358 in the placebo group reached this endpoint
T14	Participants 1970 2075	Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified.
T15	Participants 2323 2485	s the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who have a high risk of macrovascular events.
